Coronavirus and Psoriasis Reporting Registry

Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-Psoriasis) is an international, pediatric and adult registry to monitor and report on outcomes of COVID-19 occurring in psoriasis patients. We encourage psoriasis clinicians worldwide to report ALL cases of COVID-19 in their psoriasis patients, regardless of severity (including asymptomatic patients detected through public health screening).  Reporting a case to this Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE)-Psoriasis registry should take approximately 5 minutes. Please report only confirmed COVID-19 cases, and report after sufficient time has passed to observe the disease course through resolution of acute illness and/or death.

With the collaboration of our entire psoriasis community, we will rapidly be able to define the impact of COVID-19 on patients with psoriasis and how factors such as age, comorbidities, and psoriasis treatments impact COVID outcomes.

Key Points

• This is an international effort—we are counting on robust participation and collaboration.
• We will provide the psoriasis community with regularly updated summary information about reported cases, including numbers of cases by country, number of cases by treatment, etc. so the entire psoriasis community has access to these data.
• The registry contains only de-identified data, in accordance with HIPAA Safe Harbor De-Identification standards.
• The Wake Forest School of Medicine Institutional Review Board has determined that storage and analysis of de-identified data does not constitute human subjects research as defined under federal regulations [45 CFR 46.102 and 21 CFR 56.102] and does not require IRB approval.

We hope you will actively contribute to this voluntary reporting system. Through broad scale participation and collaboration, we will be able to answer these very pressing questions for our psoriasis patients and their caregivers.